The present disclosure generally relates to implantable medical devices, and more particularly, to implantable medical devices that include a radiopaque ID tag that provides identifying information regarding the implantable medical device during an imaging process such as an x-ray.
Implantable medical devices are commonly used today to monitor a patient and/or deliver therapy to a patient. For example, implantable sensors are often used to monitor one or more physiological parameters of a patient, such as heart beats, heart sounds, ECG, respiration, etc. In another example, implantable neurostimulators are used to provide neurostimulation therapy to a patient. In yet another example, pacing devices are used to treat patients suffering from various heart conditions that may result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. Such heart conditions may lead to slow, rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) are often implanted in a patient's body. Such devices may monitor and provide electrical stimulation to the heart to help the heart operate in a more normal, efficient and/or safe manner. In some applications, it may be beneficial for the implantable medical devices to include a radiopaque ID tag that permits identification of the implantable medical device during an imaging process such as an x-ray.
The present disclosure generally relates to implantable medical devices, and more particularly, to implantable medical devices including one or more radiopaque ID tags that provide identifying information regarding the implantable medical device during an imaging process such as an x-ray.
An example implantable medical device may include: a housing, a first ID tag secured relative to the housing at a first position, wherein the first ID tag defines a first radiopaque manufacturer code section that visually identifies a manufacturer of the implantable medical device, and a second ID tag secured relative to the housing at a second position, wherein the second position is offset from the first position in at least one dimension. The second ID tag may define a second radiopaque manufacturer code section that also visually identifies the manufacturer of the implantable medical device.
Alternatively or additionally to the embodiments above, the first radiopaque manufacturer code section and the second radiopaque manufacturer code section may each define one or more radiopaque alphanumeric characters.
Alternatively or additionally to any of the embodiments above, the one or more radiopaque alphanumeric characters may be configured to be human readable in an x-ray or other image of the implantable medical device.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section of the first ID tag may be structured to define a first radiopaque manufacturer code as well as a reverse image of the first radiopaque manufacturer code.
Alternatively or additionally to any of the embodiments above, at least one of the first ID tag and the second ID tag are disposed on an outer surface of the housing.
Alternatively or additionally to any of the embodiments above, at least one of the first ID tag and the second ID tag are disposed on an internal component located within the housing.
Alternatively or additionally to any of the embodiments above, the second position is offset from the first position in at least two dimensions.
Alternatively or additionally to any of the embodiments above, the housing has a cylinder along at least part of its length that includes the first position and the second position, and the second position is axially offset and radially offset from the first position.
Alternatively or additionally to any of the embodiments above, the first ID tag and the second ID tag may comprise portions of a helix structure that traverses along at least part of a length of the housing.
Alternatively or additionally to any of the embodiments above, the implantable medical device further comprises a battery, wherein at least one of the first ID tag and the second ID are disposed on or within a component of the battery.
Alternatively or additionally to any of the embodiments above, the implantable medical device further comprises a circuit board, wherein at least one of the first ID tag and the second ID tag is secured to the circuit board.
Alternatively or additionally to any of the embodiments above, the circuit board comprises at least two layers, and wherein at least one of the first ID tag and the second ID tag is positioned between two of the layers of the circuit board.
In one example, the implantable medical device may be a leadless cardiac pacemaker. In some instances, the leadless cardiac pacemaker may comprise: an elongated housing defining an energy storage section and a circuit section, an energy source disposed within the energy storage section, a circuit board disposed within the circuit section and operably coupled to the energy source, and an ID tag secured relative to the elongated housing, wherein the ID tag is configured to define a radiopaque manufacturer code that visually identifies a manufacturer of the leadless cardiac pacemaker. In some cases, two or more individual ID tags may be secured relative to the elongated housing, sometimes offset from one another in at least two dimensions.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprise an insulative coating disposed over the elongated housing, and an ID tag may be covered by the insulative coating.
Alternatively or additionally to any of the embodiments above, an ID tag may be secured to the elongated housing.
Alternatively or additionally to any of the embodiments above, the energy source may comprise a battery with a battery liner, an anode disposed within the battery liner, and a cathode disposed within the anode. An ID tag may be disposed on or in one of the battery liner, the anode and the cathode.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprise a battery pin extending from cathode of the energy source, wherein an ID tag may be disposed on or in the battery pin.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprise a desiccant, wherein an ID tag may be disposed on or in the desiccant.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprise an overmolding, wherein an ID tag may be disposed on or in the overmolding.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprises a drug collar, wherein an ID tag may be disposed on or in the drug collar.
Alternatively or additionally to any of the embodiments above, the elongated housing may comprise a proximal end feature for retrieval of the leadless cardiac pacemaker, and an ID tag may be secured to the proximal end feature.
Alternatively or additionally to any of the embodiments above, the leadless cardiac pacemaker may further comprise an axial rotation marker, and an ID tag may be disposed within or by a cutout formed in the axial rotation marker.
Alternatively or additionally to any of the embodiments above, an ID tag may be formed from a platinum wire disposed within a slot formed in the housing or other component of the leadless cardiac pacemaker.
Alternatively or additionally to any of the embodiments above, an ID tag may define an alphanumeric code that is readable by an individual during an imaging process.
Alternatively or additionally to any of the embodiments above, an ID tag may comprises an etched, machined, cut, or sintered ID tag.
Alternatively or additionally to any of the embodiments above, an ID tag may comprise a molded ID tag.
Alternatively or additionally to any of the embodiments above, an ID tag may comprise a radiopaque ink.
In another example, a leadless cardiac pacemaker may comprise: an elongated housing extending along a central axis, and an ID tag system secured relative to the elongated housing. The ID tag system may comprise a first radiopaque manufacturer code section that visually identifies a manufacturer of the implantable medical device and a second radiopaque manufacturer code section that also visually identifies the manufacturer of the implantable medical device. In some cases, the first radiopaque manufacturer code section and the second radiopaque manufacturer code section may face different radial directions relative to the central axis of the elongated housing of the leadless cardiac pacemaker.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section is the same as the second radiopaque manufacturer code section.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section may be a mirror image of the second radiopaque manufacturer code section.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section and the second radiopaque manufacturer code section may be part of a common piece.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section may be a separate piece from the second radiopaque manufacturer code section.
Alternatively or additionally to any of the embodiments above, the first radiopaque manufacturer code section may be mechanically connected to the second radiopaque manufacturer code section before and after being secured relative to the elongated housing.
Alternatively or additionally to any of the embodiments above, the ID tag system further comprises a first radiopaque MRI code section and a second radiopaque MM code section, wherein the first radiopaque MRI code section and the second radiopaque MRI code section face different radial directions relative to the central axis of the elongated housing.
The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.
The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:
While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.
In some instances, the implantable medical device 10 may include one or more ID tags that can be used to identify the implantable medical device 10 during imaging processes such as x-ray. As illustrated, the implantable medical device 10 includes a first ID tag 22, a second ID tag 24 and a third ID tag 26, shown in phantom as the third ID tag 26 is, in the illustrated orientation, on a back side of the implantable medical device 10. While three ID tags 22, 24, 26 are shown, in some cases there may be only one or two ID tags, or there may be four or more ID tags. While schematically illustrated on the housing 12, in some cases one or more of the ID tags 22, 24, 26, if present, may be located internally of the housing 12. If the first ID tag 22 is considered as being located at a first position, it can be seen that the second ID tag 24 is at a second position that is offset from the first position in at least one dimension. As illustrated, the second ID tag 24 is offset axially, along the direction of the longitudinal axis 14, as well as being offset radially, along the direction of the radial axis 20. As illustrated, the third ID tag 26 is at a third position that is offset both axially and radially from each of the first ID tag 22 and the second ID tag 24.
In some embodiments, the ID tags 22, 24, 26 may include a radiopaque identifier using a symbol and/or 1, 2 or 3 alphanumeric characters to identify a manufacturer and may include 1, 2, 3 or 4 alphanumeric characters to identify a model. The ID tags 22, 24, 26 may, for example, be used in a leadless pacemaker, a leadless pacemaker inside the heart, a dual chamber leadless pacemaker, an epicardial pacemaker, a leadless epicardial pacemaker or an implantable cardiac diagnostic device, among others. In some cases, a bar code such as a two dimensional bar code may be used. In some embodiments, the radiopaque identifier may include a two or four digit year identifier. In some cases, the radiopaque identifier may include a “B” to identify a company and a two digit model #, although this is merely illustrative.
The ID tags 22, 24, 26 are configured to be visible during imaging processes such as x-ray. With the implantable medical device 10, and thus the ID tags 22, 24 and 26, implanted within the body, the ID tags are configured to be visible and readable by an imaging process instituted from outside of the body. The imaging process may use x-rays, or any other suitable penetrating wave or particle such as neutron beams or gamma rays, as desired. In some cases, the ID tags 22, 24, 26, or portions thereof, are radiopaque. In some instances, the first ID tag 22 defines a first radiopaque manufacturer code section 28 that visually identifies a manufacturer of the implantable medical device 10, and the second ID tag 24 defines a second radiopaque manufacturer code section 30 that also visually identifies the manufacturer of the implantable medical device 10. In some cases, the first ID tag 22 and/or the second ID tag 24 may include a non-radiopaque substrate or carrier, and only the first radiopaque manufacturer code section 28 and/or the second radiopaque manufacturer code 30 is/are radiopaque. In some cases, the substrate or carrier forming the first ID tag 22 and/or the second ID tag 24 are radiopaque, and the first radiopaque manufacturer code section 28 and/or the second radiopaque manufacturer code section 30 represents an absence of radiopaque material. In some instances, the first ID tag 22 and/or the second ID tag 24 may be formed by printing alphanumeric characters or other identifying symbols onto a substrate or carrier using a radiopaque ink. In some cases, an ID tag 22, 24, 26 may be formed as a label or sticker that may be adhesively secured to a component within the implantable medical device 10. An ID tag 22, 24, 26 may, for example, include a high atomic weight foil. In some cases, an ID tag 22, 24, 26 may include a platinum foil that is enclosed in heat shrink tubing around an internal component such as a battery.
It will be appreciated that by including two or more radiopaque ID tags, arranged at offset positions, it may be easier to read at least one of the ID tags during an imaging process, especially for implantable medical devices that do not have a well-defined or fixed implanted orientation. While the first radiopaque manufacturer code section 28 is illustrated as “XXX” and the second radiopaque manufacturer code section 30 is illustrated as “YYY”, it will be appreciated that this is illustrative only, as any variety of codes such as bar codes, alphanumeric characters, or any other suitable code or marking may be used, as desired.
In some embodiments, an ID tag may include a radiopaque manufacturer code as well as a mirror image of the radiopaque manufacturer code.
As noted above, the implantable medical device 10 (
As seen in
Starting with the energy storage section 54, the illustrative leadless cardiac pacemaker 48 includes a housing 68 that includes the aforementioned proximal end feature 64. In some cases, as illustrated, an insulative coating 70 is disposed over at least a portion of the housing 68. The insulative coating 70 may be formed of parylene, but this is not required. The next several components form part of a battery 72. The illustrative battery 72 includes a battery liner 74, an anode 76 and a cathode 78. Several components pertain to the battery 72, including a battery feedthrough 88, a battery lid 90 and a battery pin 92. It will be appreciated that the battery 72 includes additional components and materials that, for simplicity, are not illustrated. The illustrative leadless cardiac pacemaker 48 includes a first ID tag 58, a second ID tag 60 and a third ID tag 62, each tag reading “BSC140” as an illustrative but non-limiting example. It can be seen that the second ID tag 60 is axially and radially offset from the first ID tag 58, and that the third ID tag 62 is axially and radially offset from the first ID tag 58 and the second ID tag 60. In the illustrated embodiment, the ID tags 58, 60 and 62 are located in or on the energy storage section 54 of the leadless cardiac pacemaker 48.
Moving to the circuit section 56, the illustrative leadless cardiac pacemaker 48 includes the electrode 66 and a drug collar 82 that is disposed proximate the electrode 66. An epoxy overmolding 84 sits under the drug collar 82. A ferrule 86 sits beneath the epoxy overmolding 84. A stacked printed circuit board 96 sits within a liner 98. As will be illustrated in subsequent Figures, a number of these components can be used or modified to carry or otherwise provide radiopaque ID tags such as those discussed with respect to
While each of
As depicted in
Electrodes 114 and/or 114′ may have any of a variety of sizes and/or shapes, and may be spaced at any of a variety of distances. For example, electrodes 114 may have a diameter of two to twenty millimeters (mm). However, in other examples, electrodes 114 and/or 114′ may have a diameter of two, three, five, seven millimeters (mm), or any other suitable diameter, dimension and shape. Example lengths for electrodes 114 and/or 114′ include a length of zero, one, three, five, ten millimeters (mm), or any other suitable length. As used herein, the length is a dimension of electrodes 114 and/or 114′ that extends outward from housing 120. Additionally, at least some of electrodes 114 and/or 114′ may be spaced from one another by a distance of twenty, thirty, forty, fifty millimeters (mm), or any other suitable distance. The electrodes 114 and/or 114′ of a single device may have different sizes with respect to each other, and the spacing of the electrodes on the device may not be uniform.
Communication module 102 may be electrically coupled to electrodes 114 and/or 114′ and configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and the like. Communication pulses, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some examples, communication pulses are limited to only including sub-threshold signals which convey information. Other devices that communication module 102 may be configured to communicate with may be located either external or internal to the patient's body. Communication module 102 may additionally be configured to sense for communication pulses delivered by the other devices, which are located externally to LCP 100. Irrespective of the location, LCP and the other devices may communicate with each other via communication module 102 to accomplish one or more desired functions. Some example functions include storing communicated data, using communicated data for determining occurrences of arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions.
LCP 100 and the other devices may use the delivered communication pulses to communicate raw information, processed information, messages, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed ECG), signals gathered from coupled sensors, and the like. In some examples, the raw information may include signals that have been filtered using one or more signal processing techniques. Processed information may include any information that has been determined by LCP 100. For example, processed information may include a determined heart rate, timings of determined heartbeats, timings of other determined events, determinations of threshold crossings, expirations of monitored time periods, and determined parameters such as activity parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. Messages may include instructions directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device or writing data to the receiving device.
In at least some examples, communication module 102 (or LCP 100) may further include switching circuitry to selectively connect one or more of electrodes 114 and/or 114′ to communication module 102 in order to select via which electrodes 114 and/or 114′ communication module 102 delivers the communication pulses. Additionally, communication module 102 may be configured to use one or more methods for communicating with other devices. For example, communication module 102 may communicate via conducted signals, radiofrequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other signals or methods suitable for communication.
Pulse generator module 104 of LCP 100 may also be electrically connected to one or more of electrodes 114 and/or 114′. Pulse generator module 104 may be configured to generate electrical stimulation pulses and deliver the electrical stimulation pulses to tissues of a patient via electrodes 114 and/or 114′ electrodes in order to effectuate one or more electrical stimulation therapies. Electrical stimulation pulses as used herein are meant to encompass any electrical signals that may be delivered to tissue of a patient for purposes of treatment of any type of disease or abnormality. When used to treat heart diseases or abnormalities, the electrical stimulation pulses may generally be configured so as to capture the heart of the patient—cause the heart to contract in response to the delivered electrical stimulation pulse. In at least examples where pulse generator 104 is configured to generate specific types of electrical stimulation pulses termed defibrillation/cardioversion pulses, pulse generator module 104 may include one or more capacitor elements.
Pulse generator module 104 may include capability to modify the electrical stimulation pulses, such as by adjusting a pulse width or amplitude of the electrical stimulation pulses, in order to ensure that the delivered electrical stimulation pulses consistently capture the heart. Pulse generator module 104 may use energy stored in energy storage module 112 to generate the electrical stimulation pulses. In at least some examples, pulse generator module 104 (or LCP 100) may further include switching circuitry to selectively connect one or more of electrodes 114 and/or 114′ to pulse generator module 104 in order to select via which electrodes 114 and/or 114′ pulse generator 104 delivers the electrical stimulation pulses.
In some examples, LCP 100 may include electrical sensing module 106 and mechanical sensing module 108. Electrical sensing module 106 may be configured to sense intrinsic cardiac electrical signals conducted from electrodes 114 and/or 114′ to electrical sensing module 106. For example, electrical sensing module 106 may be electrically connected to one or more electrodes 114 and/or 114′ and electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through electrodes 114 and/or 114′. In some examples, the cardiac electrical signals may represent local information from the chamber in which LCP 100 is implanted. For instance, if LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by LCP 100 through electrodes 114 and/or 114′ may represent ventricular cardiac electrical signals. Mechanical sensing module 108 may include, or be electrically connected to, various sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. Mechanical sensing module 108 may gather signals from the sensors indicative of the various physiological parameters. Both electrical sensing module 106 and mechanical sensing module 108 may be further connected to processing module 110 and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to processing module 110. Although described with respect to
Processing module 110 may be configured to control the operation of LCP 100. For example, processing module 110 may be configured to receive cardiac electrical signals from electrical sensing module 106 and/or physiological signals from mechanical sensing module 108. Based on the received signals, processing module 110 may determine occurrences and types of arrhythmias. Processing module 110 may further receive information from communication module 102. In some examples, processing module 110 may additionally use such received information to determine occurrences and types of arrhythmias. However, in other examples, LCP 100 may use the received information instead of the signals received from electrical sensing module 106 and/or mechanical sensing module 108—for instance if the received information is more accurate than the signals received from electrical sensing module 106 and/or mechanical sensing module 108 or if electrical sensing module 106 and/or mechanical sensing module 108 have been disabled or omitted from LCP 100.
Based on any determined arrhythmias, processing module 110 may then control pulse generator module 104 to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapies to treat the determined arrhythmias. For example, processing module 110 may control pulse generator module 104 to generate pacing pulses with varying parameters and in different sequences to effectuate one or more electrical stimulation therapies. In controlling pulse generator module 104 to deliver bradycardia pacing therapy, processing module 110 may control pulse generator module 104 to deliver pacing pulses designed to capture the heart of the patient at a regular interval to prevent the heart of a patient from falling below a predetermined threshold. For ATP therapy, processing module 110 may control pulse generator module 104 to deliver pacing pulses at a rate faster than an intrinsic heart rate of a patient in attempt to force the heart to beat in response to the delivered pacing pulses rather than in response to intrinsic cardiac electrical signals. Processing module 110 may then control pulse generator module 104 to reduce the rate of delivered pacing pulses down to a safe level. In CRT, processing module 110 may control pulse generator module 104 to deliver pacing pulses in coordination with another device to cause the heart to contract more efficiently. Additionally, in cases where pulse generator module 104 is capable of generating defibrillation and/or cardioversion pulses for defibrillation/cardioversion therapy, processing module 110 may control pulse generator module 104 to generate such defibrillation and/or cardioversion pulses. In other examples, processing module 110 may control pulse generator module 104 to generate electrical stimulation pulses to provide electrical stimulation therapies different than those described herein to treat one or more detected cardiac arrhythmias.
Aside from controlling pulse generator module 104 to generate different types of electrical stimulation pulses and in different sequences, in some examples, processing module 110 may also control pulse generator module 104 to generate the various electrical stimulation pulses with varying pulse parameters. For example, each electrical stimulation pulse may have a pulse width and a pulse amplitude. Processing module 110 may control pulse generator module 104 to generate the various electrical stimulation pulses with specific pulse widths and pulse amplitudes. For example, processing module 110 may cause pulse generator module 104 to adjust the pulse width and/or the pulse amplitude of electrical stimulation pulses if the electrical stimulation pulses are not effectively capturing the heart. Such control of the specific parameters of the various electrical stimulation pulses may ensure that LCP 100 is able to provide effective delivery of electrical stimulation therapy.
In some examples, processing module 110 may further control communication module 102 to send information to other devices. For example, processing module 110 may control communication module 102 to generate one or more communication pulses for communicating with other devices of a system of devices. For instance, processing module 110 may control communication module 102 to generate communication pulses in particular sequences, where the specific sequences convey different data to other devices. Communication module 102 may also conduct any received communication signals to processing module 110 for potential action by processing module 110.
In further examples, processing module 110 may additionally control switching circuitry by which communication module 102 and pulse generator module 104 deliver communication pulses and electrical stimulation pulses to tissue of the patient. As described above, both communication module 102 and pulse generator module 104 may include circuitry for connecting one or more electrodes 114 and/114′ to communication module 102 and pulse generator module 104 so those modules may deliver the communication pulses and electrical stimulation pulses to tissue of the patient. The specific combination of one or more electrodes by which communication module 102 and pulse generator module 104 deliver communication pulses and electrical stimulation pulses influence the reception of communication pulses and/or the effectiveness of electrical stimulation pulses. Although it was described that each of communication module 102 and pulse generator module 104 may include switching circuitry, in some examples LCP 100 may have a single switching module connected to all of communication module 102, pulse generator module 104, and electrodes 114 and/or 114′. In such examples, processing module 110 may control the single switching module to connect modules 102/104 and electrodes 114/114′.
In still additional examples, processing module 110 may control pulse generator module 104 to generate the communication pulses for communicating with external devices. In such examples, communication module 102 may not include the capability to generate communication pulses. In some even additional examples, electrical sensing module 106 may further include the capability to sense communication pulses. In such examples, electrical sensing module 106 may communicate any received communication pulses to processing module 110. In such examples, LCP 100 may not include communication module 102, as the functions of communication module 102 are subsumed within pulse generator module 104 and electrical sensing module 106. However, in such examples, LCP 100 may not be able to simultaneously generate both communication pulses and electrical stimulation pulses.
In some examples, processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of LCP 100. By using a pre-programmed chip, processing module 110 may use less power than other programmable circuits while able to maintain basic functionality, thereby increasing the battery life of LCP 100. In other examples, processing module 110 may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of LCP 100 after manufacture, thereby allowing for greater flexibility of LCP 100 than when using a pre-programmed chip.
Processing module 110, in additional examples, may further include a memory circuit and processing module 110 may store information on and read information from the memory circuit. In other examples, LCP 100 may include a separate memory circuit (not shown) that is in communication with processing module 110, such that processing module 110 may read and write information to and from the separate memory circuit. The memory circuit, whether part of processing module 110 or separate from processing module 110 may have address lengths of, for example, eight bits. However, in other examples, the memory circuit may have address lengths of sixteen, thirty-two, or sixty-four bits, or any other bit length that is suitable. Additionally, the memory circuit may be volatile memory, non-volatile memory, or a combination of both volatile memory and non-volatile memory.
Energy storage module 112 may provide a power source to LCP 100 for its operations. In some examples, energy storage module 112 may be a non-rechargeable lithium-based battery. In other examples, the non-rechargeable battery may be made from other suitable materials known in the art. Because LCP 100 is an implantable device, access to LCP 100 may be limited. In such circumstances, it is necessary to have sufficient energy capacity to deliver therapy over an extended period of treatment such as days, weeks, months, or years. In some examples, energy storage module 112 may a rechargeable battery in order to facilitate increasing the useable lifespan of LCP 100. In still other examples, energy storage module 112 may be other types of energy storage devices such as capacitors.
To implant LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, LCP 100 may include one or more anchors 116. Anchor 116 may include any number of fixation or anchoring mechanisms. For example, anchor 116 may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some examples, although not shown, anchor 116 may include threads on its external surface that may run along at least a partial length of anchor 116. The threads may provide friction between the cardiac tissue and the anchor to help fix anchor 116 within the cardiac tissue. In other examples, anchor 116 may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.
The modules shown in
In some examples, each island section may be circular in shape, but this is not required. In some cases, each island section has a diameter that is less than an inner diameter of a cross section of an implantable medical device housing (such as LCP 100) so that the circuit 400 may fit once folded into a stacked configuration. Example diameters range from 3.8 to 12.7 millimeters (mm). The island sections may be triangular, square, ovoid or any other desired shape. In some cases, the flexible ribbon sections may range from 3.8 to 12.7 mm.
Processing module 410 and circuit elements 408A-H may be examples of circuit elements that may implement the functions of communication module 102, pulse generator module 104, electrical sensing module 106, mechanical sensing module 108, and/or processing module 110. Processing module 410 may include any of the circuit elements or components described with respect to processing module 110, such as a pre-programmed logic chip or a programmable microprocessor. Circuit elements 408A-H may represent capacitors, resistors, diodes, ASICS, and/or any other suitable circuit elements or components.
In some examples, at least one island section may have one or more components affixed to both major opposing surfaces of that island section. In the specific example of
Ribbon sections 406, 407 may include traces, such as trace 422 in first ribbon section 406 and trace 423 in second ribbon section 407. Traces 422, 423 may be conductive and thereby electrically connect certain components on island sections 401, 403, and 405. First and second ribbon sections 406, 407 may be relatively more flexible than island sections 401, 403, and 405. For example, first and second ribbon sections 406, 407 may be made from a flexible substrate, such as a polymer, with traces 422, 423 embedded within the flexible substrate while island sections 401, 403, and 405 include more rigid PCBs. Alternatively, where island sections 401, 403, and 405 and first and second ribbon sections 406, 407 share a common substrate, first and second ribbon sections 406, 407 may be relatively thinner than island sections 401, 403, and 405.
Additionally, in at least some examples, first ribbon section 406 and second ribbon section 407 may have differing lengths. As depicted in
In some embodiments, the island sections 401, 402, 403 may include rigid printed circuit boards, with metal or other traces electrically connecting each of the components on each of the island sections 401, 402, 403. Ribbon sections 406, 407 may include a flexible substrate, such as a polymer including a polyimide. Traces may be embedded within the ribbon sections 406, 407 to provide electrical communication therethrough. In some cases, a common substrate may instead extend through the island sections 401, 402, 403 and through the ribbon sections 406, 407. The island sections 401, 402, 403 may include a multi-layered substrate that includes alternating conductive substrates and non-conductive substrates while the ribbon sections 406, 407 are thinner and thus more flexible. In at least some examples, the conductive substrate may be metal, or other suitable conductive material, and the non-conductive substrate may be a type of polymer, such as a polyamide or other suitable non-conductive material. Further details regarding the construction of the circuit 400 may be found in U.S. Provisional Application No. 62/086,015 filed Dec. 1, 2014, which application is incorporated by reference herein in its entirety.
In some examples, a filler material may be disposed within spaces 431 and 432 in order isolate processing module 410 and circuit elements 408A-H disposed on different island sections. In at least some examples, the filler material may be formed such that when the filler material is disposed within spaces 431 and/or 432, the filler material folds around the processing module 410 and/or circuit elements 408A-H to isolate even the components on the same island section. In some examples, the isolation that the filler material provides may be electrical isolation. For instance, the filler material may prevent the components on islands 401, 403, and/or 405 from contacting each other and causing a short circuit. In other examples, the filler material may instead, or additionally, provide mechanical isolation between the components of islands 401, 403, and/or 405. For instance, the device housing islands 401, 403, and/or 405 may be subjected to motion, and the filler material may prevent the components of islands 401, 403, and/or 405 from striking each other and causing damage. In at least some examples, the filler material may be a desiccant. Some example filler materials include silicone or other inert compounds.
In some embodiments, the island sections 502, 504 may include one or more ID tags. For example, in some cases, an ID tag 510 may be printed or otherwise formed on an outer surface of an island section such as the island section 502. In some cases, an island section such as the island section 504 may include several layers 504a and 504b, for example, and an ID tag 512 may be disposed between the layers 504a and 504b. In some cases, an ID tag may be disposed on the back of the ASIC and/or adhesively secured to any of the electronic components present in the circuit 400 (
In some embodiments, a radiopaque ID tag may be formed by first etching alphanumeric characters or other symbols into a substrate, then filling the etching with a radiopaque material.
The previous Figures illustrate various parts of an implantable medical device, such as a leadless pacemaker, that include one or more radiopaque ID tags that are secured relative to the part, or formed within the part.
In the example shown, each plane 478, 480 and 482 includes one or more characters. As illustrated, the first plane 478 includes several characters 484, the second plane 480 includes several characters 486 and the third plane 482 includes several characters 488. As shown, each of the characters 484, 486 and 488 spell out “BSC 140”, but this is merely illustrative. In some cases, the characters 484, 486 and 488 may all be different. In the example shown, the characters 484, 486 and 488 are each formed by cutting, etching or otherwise removing radiopaque material to form the characters 484, 486 and 488. In some cases, the characters 484, 486 and 488 are apertures that extends all the way through the battery cathode 476 as shown. In other cases, the characters 484, 486 and 488 are depressions that extends only part way through the battery cathode 476. In either cases, the characters 484, 486 and 488 may show up in an x-ray as relatively darker than the rest of the battery cathode 476. It will be appreciated that by creating each plane in a different orientation, it may be easier to read in an x-ray, regardless of the position of the device that includes the battery cathode 476.
In some instances, the battery cathode 476 may be made from a solid piece of radiopaque material. In other cases, the battery cathode 476 may be made from a non-radiopaque substrate that is coated with a radiopaque material. When the battery cathode 476 is made from a non-radiopaque substrate that is coated with a radiopaque material, the characters 484, 486 and 488 may be formed by etching through the radiopaque material to form an image of the characters 484, 486 and 488, or a reverse image of the characters 484, 486 and 488, under x-ray radiation, as desired.
While
Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific examples described and contemplated herein. For instance, as described herein, various examples include one or more modules described as performing various functions. However, other examples may include additional modules that split the described functions up over more modules than that described herein. Additionally, other examples may consolidate the described functions into fewer modules. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.
This application is a continuation of co-pending U.S. patent application Ser. No. 15/018,379, filed Feb. 8, 2016 and entitled “Implantable Medical Device With Radiopaque ID Tag”, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/113,827 filed on Feb. 9, 2015, and also claims the benefit of U.S. Provisional Patent Ser. No. 62/138,799 filed on Mar. 26, 2015, all of which are incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
62138799 | Mar 2015 | US | |
62113827 | Feb 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15018379 | Feb 2016 | US |
Child | 16042616 | US |